Mouse models of human myeloma.
Multiple myeloma (MM) remains incurable despite high-dose chemotherapy with stem cell support. There is need, therefore, for continuous efforts directed toward the development of novel rational-based therapeutics for MM, which requires a detailed knowledge of the mutations driving this malignancy. In improving the success rate of effective drug development, it is equally imperative that biologic systems be developed to better validate these target genes. Here we review the recent developments in the generation of mouse models of MM and their impact as preclinical models for designing and assessing target-based therapeutic approaches.
Mitsiades
Constantine S
CS
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. constantine_mitsiades@dfci.harvard.edu
Anderson
Kenneth C
KC
Carrasco
Daniel R
DR
D000818:Animals; D016025:Bone Transplantation; D002678:Chimera / Q000276:immunology / Q000502:physiology*; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D008822:Mice, Transgenic; D009101:Multiple Myeloma / Q000503:physiopathology*; D014183:Transplantation, Heterologous / Q000276:immunology / Q000379:methods